Fig. 4: BTK inhibitor class adverse event rates in the ASPEN Phase III trial. | Leukemia

Fig. 4: BTK inhibitor class adverse event rates in the ASPEN Phase III trial.

From: Managing Waldenström’s macroglobulinemia with BTK inhibitors

Fig. 4

All grade and Grade 3 events of interest reported with ibrutinib and zanubrutinib monotherapy in the ASPEN Phase III trial. Adapted from [32]. aMajor hemorrhage was defined as serious or grade ≥3 bleeding at any site, or central nervous system bleeding of any grade. AESI adverse event of special interest.

Back to article page